Professor | Yu Xiong Feng | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Yu Xiong Feng
Contact Information	yxfeng@zju.edu.cn
Language ability	Chinese, English
Province	Zhejiang

Upload Avatar (500 x 500)

Name

Yu Xiong Feng

Contact Information

yxfeng@zju.edu.cn

Language ability

Chinese, English

Province

Zhejiang

University/Lab Affiliation and Title	Zhejiang University
Faculty	Medical
Academic Background & Achievements	2004-2010 PhD in Biochemistry and Molecular Biology: Shanghai Institute of Life Sciences, Chinese Academy of Sciences 2000-2004 Bachelor's in Biotechnology: College of Life Sciences, Zhejiang University Core Member of Zhejiang Provincial Leading Innovation Team Selected for the National Overseas High-Level Talent Program
Work Experience	2018-present - Zhejiang University Translational Medicine Institute/Zhejiang University First Affiliated Hospital - Researcher/Joint Professor 2010-2017 - Massachusetts Institute of Technology - Postdoctoral Researcher

University/Lab Affiliation and Title

Zhejiang University

Faculty

Medical

Academic Background & Achievements

2004-2010 PhD in Biochemistry and Molecular Biology: Shanghai Institute of Life Sciences, Chinese Academy of Sciences
2000-2004 Bachelor's in Biotechnology: College of Life Sciences, Zhejiang University
Core Member of Zhejiang Provincial Leading Innovation Team
Selected for the National Overseas High-Level Talent Program

Work Experience

2018-present - Zhejiang University Translational Medicine Institute/Zhejiang University First Affiliated Hospital - Researcher/Joint Professor
2010-2017 - Massachusetts Institute of Technology - Postdoctoral Researcher

Areas of Focus	Molecular Mechanisms of Tumor Metastasis Role of Cellular Metabolism and Stress in Tumor Drug Resistance Construction and Clinical Application of 'Normal Tissue-Tumor Tissue' 3D Co-evolution Model
Publications	Glutamine synthetase licenses APC/C-mediated mitotic progression to drive cell growth, Zhao JS, Shi S, Qu HY, et al., Liang T, Lu Z, Feng YX, 2022 Transcriptional Control of Metastasis by Integrated Stress Response Signaling, Lu S, Yang LX, Cao ZJ, Zhao JS, You J, Feng YX, 2021 Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells, Feng M, Jin JQ, Xia L, et al., Feng YX, Zhu D, 2019 Cancer-specific PERK signaling drives invasion and metastasis through CREB3L1, Feng YX, Jin DX, Sokol ES, Reinhardt F, Miller DH, Gupta PB, 2017 SMARCE1 is required for the invasive progression of in situ cancers, Sokol ES, Feng YX, Jin DX, Tizabi MD, Miller DH, et al., 2017 Epithelial-to-mesenchymal transition activates PERK-eIF2alpha and sensitizes cells to endoplasmic reticulum stress, Feng YX, Sokol ES, Del Vecchio CA, Sanduja S, Claessen JH, et al., 2014 The endoplasmic reticulum may be an Achilles' heel of cancer cells that have undergone an epithelial-to-mesenchymal transition, Feng YX, Sokol ES, Gupta PB, 2014 Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model, Feng YX, Wang T, Deng YZ, Yang P, Li JJ, et al., 2011 Liver cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF-kappaB signaling pathway, Feng YX, Zhao JS, Li JJ, Wang T, Cheng SQ, et al., 2010

Areas of Focus

Molecular Mechanisms of Tumor Metastasis
Role of Cellular Metabolism and Stress in Tumor Drug Resistance
Construction and Clinical Application of 'Normal Tissue-Tumor Tissue' 3D Co-evolution Model

Publications

Glutamine synthetase licenses APC/C-mediated mitotic progression to drive cell growth, Zhao JS, Shi S, Qu HY, et al., Liang T, Lu Z, Feng YX, 2022
Transcriptional Control of Metastasis by Integrated Stress Response Signaling, Lu S, Yang LX, Cao ZJ, Zhao JS, You J, Feng YX, 2021
Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells, Feng M, Jin JQ, Xia L, et al., Feng YX, Zhu D, 2019
Cancer-specific PERK signaling drives invasion and metastasis through CREB3L1, Feng YX, Jin DX, Sokol ES, Reinhardt F, Miller DH, Gupta PB, 2017
SMARCE1 is required for the invasive progression of in situ cancers, Sokol ES, Feng YX, Jin DX, Tizabi MD, Miller DH, et al., 2017
Epithelial-to-mesenchymal transition activates PERK-eIF2alpha and sensitizes cells to endoplasmic reticulum stress, Feng YX, Sokol ES, Del Vecchio CA, Sanduja S, Claessen JH, et al., 2014
The endoplasmic reticulum may be an Achilles' heel of cancer cells that have undergone an epithelial-to-mesenchymal transition, Feng YX, Sokol ES, Gupta PB, 2014
Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model, Feng YX, Wang T, Deng YZ, Yang P, Li JJ, et al., 2011
Liver cancer: EphrinA2 promotes tumorigenicity through Rac1/Akt/NF-kappaB signaling pathway, Feng YX, Zhao JS, Li JJ, Wang T, Cheng SQ, et al., 2010

Tumor Metastasis Molecular Mechanisms Cellular Metabolism Stress Drug Resistance 3D Model Normal Tissue Tumor Tissue Clinical Application

Jun Zhang - Zhejiang University

Hangping Yao - Zhejiang University

Jun Jie Xu - Zhejiang University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us